JP2010500284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500284A5 JP2010500284A5 JP2009515468A JP2009515468A JP2010500284A5 JP 2010500284 A5 JP2010500284 A5 JP 2010500284A5 JP 2009515468 A JP2009515468 A JP 2009515468A JP 2009515468 A JP2009515468 A JP 2009515468A JP 2010500284 A5 JP2010500284 A5 JP 2010500284A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mammals
- humans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 CCCC(C1C(/C(/C=*/CC2C)=C/C=C2/C(F)(F)F)=O)C1(C)/C(/C(C)C/C(/C)=C1)=C/C=C1\c1nc(N(CCC)C(N(C2CC2)C2=O)=O)c2[n]1C1CCC1 Chemical compound CCCC(C1C(/C(/C=*/CC2C)=C/C=C2/C(F)(F)F)=O)C1(C)/C(/C(C)C/C(/C)=C1)=C/C=C1\c1nc(N(CCC)C(N(C2CC2)C2=O)=O)c2[n]1C1CCC1 0.000 description 2
- SHWCLAKWPQCZNV-UHFFFAOYSA-N CCCN(c1c(C(N2C3CC3)=O)[nH]c(-c(cc3)cnc3N(CC)C(c3ccc(C(F)(F)F)nc3)=N)n1)C2=O Chemical compound CCCN(c1c(C(N2C3CC3)=O)[nH]c(-c(cc3)cnc3N(CC)C(c3ccc(C(F)(F)F)nc3)=N)n1)C2=O SHWCLAKWPQCZNV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80503006P | 2006-06-16 | 2006-06-16 | |
| US60/805,030 | 2006-06-16 | ||
| US80556406P | 2006-06-22 | 2006-06-22 | |
| US60/805,864 | 2006-06-22 | ||
| US11/811,823 US7884100B2 (en) | 2006-06-16 | 2007-06-12 | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US11/811,823 | 2007-06-12 | ||
| PCT/US2007/013849 WO2007149277A2 (en) | 2006-06-16 | 2007-06-13 | Substituted 8-[6-amino-3-pyridyl]xanthines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500284A JP2010500284A (ja) | 2010-01-07 |
| JP2010500284A5 true JP2010500284A5 (OSRAM) | 2010-07-22 |
| JP5417558B2 JP5417558B2 (ja) | 2014-02-19 |
Family
ID=56290980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515468A Expired - Fee Related JP5417558B2 (ja) | 2006-06-16 | 2007-06-13 | 置換８−［６−アミノ−３−ピリジル］キサンチン類 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7884100B2 (OSRAM) |
| EP (1) | EP2029143B1 (OSRAM) |
| JP (1) | JP5417558B2 (OSRAM) |
| KR (1) | KR101413404B1 (OSRAM) |
| CN (1) | CN103145712A (OSRAM) |
| AU (1) | AU2007261568B2 (OSRAM) |
| BR (1) | BRPI0712001B8 (OSRAM) |
| CA (1) | CA2655598C (OSRAM) |
| DK (1) | DK2029143T3 (OSRAM) |
| EA (1) | EA016791B1 (OSRAM) |
| ES (1) | ES2548437T3 (OSRAM) |
| HU (1) | HUE026457T2 (OSRAM) |
| IL (1) | IL195916A (OSRAM) |
| MX (1) | MX2008015954A (OSRAM) |
| MY (1) | MY152178A (OSRAM) |
| NZ (1) | NZ597222A (OSRAM) |
| PL (1) | PL2029143T3 (OSRAM) |
| PT (1) | PT2029143E (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| US7579348B2 (en) * | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| WO2006091936A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| WO2022246392A1 (en) | 2021-05-18 | 2022-11-24 | Purnovate, Inc. | Cyclic amide-containing pyridyl xanthines as a 2b antagonists |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6060481A (en) | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
| GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| KR20030031466A (ko) * | 2000-02-17 | 2003-04-21 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 포유동물 세포 증식을 조절하기 위한 ａ２ｂ 아데노신수용체 길항 물질의 동정 및 사용 방법 |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| PL370207A1 (en) | 2001-11-09 | 2005-05-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
| US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| WO2003063800A2 (en) | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
| US7034070B2 (en) * | 2002-09-27 | 2006-04-25 | Vincent Chuang | Arylalkyl aminofunctional silanes for epoxy laminates |
| US7148229B2 (en) | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| RS52455B (sr) | 2004-09-01 | 2013-02-28 | Gilead Sciences Inc. | Postupak zarastanja rana primenom antagonista adenozinskog a2b receptora |
| US20060053029A1 (en) | 2004-09-03 | 2006-03-09 | Butler Keith R | Methods and systems for providing an enterprise supply management portal |
| US20060159627A1 (en) | 2004-10-15 | 2006-07-20 | Dewan Zeng | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| WO2006091898A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| WO2006091936A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| US7579348B2 (en) * | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| WO2006091896A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyridyl substituted xanthines |
| JP5044823B2 (ja) | 2005-06-16 | 2012-10-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ａ２ｂアデノシンレセプターアンタゴニストのプロドラッグ |
| MX2008011828A (es) * | 2006-03-17 | 2008-09-29 | Cv Therapeutics Inc | Metodo para la prevencion y el tratamiento de enfermedad hepatica utilizando antagonistas del receptor de adenosina a2b. |
| CA2652858A1 (en) * | 2006-06-15 | 2007-12-27 | Targeted Genetics Corporation | Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7767685B2 (en) | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| JP5460690B2 (ja) | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
-
2007
- 2007-06-12 US US11/811,823 patent/US7884100B2/en not_active Expired - Fee Related
- 2007-06-13 BR BRPI0712001A patent/BRPI0712001B8/pt active IP Right Grant
- 2007-06-13 EA EA200900010A patent/EA016791B1/ru unknown
- 2007-06-13 PL PL07796049T patent/PL2029143T3/pl unknown
- 2007-06-13 NZ NZ597222A patent/NZ597222A/xx unknown
- 2007-06-13 HU HUE07796049A patent/HUE026457T2/en unknown
- 2007-06-13 EP EP07796049.0A patent/EP2029143B1/en active Active
- 2007-06-13 CN CN2013100513402A patent/CN103145712A/zh active Pending
- 2007-06-13 JP JP2009515468A patent/JP5417558B2/ja not_active Expired - Fee Related
- 2007-06-13 PT PT77960490T patent/PT2029143E/pt unknown
- 2007-06-13 MX MX2008015954A patent/MX2008015954A/es active IP Right Grant
- 2007-06-13 MY MYPI20084937 patent/MY152178A/en unknown
- 2007-06-13 DK DK07796049.0T patent/DK2029143T3/en active
- 2007-06-13 CA CA2655598A patent/CA2655598C/en active Active
- 2007-06-13 AU AU2007261568A patent/AU2007261568B2/en active Active
- 2007-06-13 KR KR1020097000879A patent/KR101413404B1/ko active Active
- 2007-06-13 ES ES07796049.0T patent/ES2548437T3/es active Active
-
2008
- 2008-12-14 IL IL195916A patent/IL195916A/en active IP Right Grant
-
2010
- 2010-12-14 US US12/967,876 patent/US8258142B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063088A5 (OSRAM) | ||
| RU2470016C2 (ru) | Производное бипиразола | |
| JP2009535352A5 (OSRAM) | ||
| JP2012532874A5 (OSRAM) | ||
| JP2009502743A5 (OSRAM) | ||
| JP2013518107A5 (OSRAM) | ||
| JP2010500284A5 (OSRAM) | ||
| JP2013509429A5 (OSRAM) | ||
| JP2013542247A5 (OSRAM) | ||
| JP2012255026A5 (OSRAM) | ||
| JP2006143751A5 (OSRAM) | ||
| JP2006523216A5 (OSRAM) | ||
| JP2018507914A5 (OSRAM) | ||
| JP2013507439A5 (OSRAM) | ||
| JP2011522816A5 (OSRAM) | ||
| EP2011487A3 (en) | Pharmaceutical compositions for gastroinetestinal drug delivery | |
| JP2013519645A5 (OSRAM) | ||
| JP2006526590A5 (OSRAM) | ||
| JP2007514005A5 (OSRAM) | ||
| JP2014526503A5 (OSRAM) | ||
| JP2008539268A5 (OSRAM) | ||
| JP2009511568A5 (OSRAM) | ||
| JP2008513510A5 (OSRAM) | ||
| JP2014503593A5 (OSRAM) | ||
| JP2017501140A5 (OSRAM) |